^
    Back
    Association details:
    Biomarker:PD-L1 negative + KRAS G12C
    Cancer:Non Small Cell Lung Cancer
    Drug Class:Immunotherapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2023
    Title:

    The impact of PD-L1 expression and co-mutations on outcome of KRAS-driven non-small-cell lung cancer.

    Published date:
    05/25/2023
    Excerpt:
    In addition, specifically within the PD-L1neg subset, OS was longer for KRASG12C compared to KRASother patients (22.6 months vs. 12.1 months, p = 0.032). This was driven by the longer PFS under CHT-IO (9.7 vs. 4.5 months for KRASG12Cvs.KRASother, p = 0.005)...
    Secondary therapy:
    Chemotherapy
    DOI:
    10.1200/JCO.2023.41.16_suppl.9090